-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
ZLM-66
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/zlm-66.gif)
| Category | Human immunodeficiency Virus (HIV) |
| Description | ZLM-66 is a potent non-nucleoside reverse transcriptase inhibitor (NNRTIs) with an IC50 of 41 nM for wild-type (WT) HIV-1 reverse transcriptase and an EC50 value of 13 nM for wild-type HIV-1. ZLM-66 is a Doravirine (HY-16767) analogs. ZLM-66 can be used for the research of AIDS. |
Product Information
| Synonyms | ZLM-66|CS-0564112 |
| Molecular Weight | 481.43 |
| Molecular Formula | C24H18F3N5O3 |
| Canonical SMILES | CC1=CC(=CC=C1)C2=CC(=CC(=C2)C#N)OC3=C(C=CN(C3=O)CC4=NNC(=O)N4C)C(F)(F)F |
| Purity | ≥98% (HPLC) |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Complexity | 1010 |
| Exact Mass | 481.13617394 |
| In Vitro | ZLM-66 (0.0016-125 µg/ml, 5 d) inhibits HIV-1 and HIV-1 mutant strains in MT-4 cells. |
| In Vivo | Zlm-66 (1-5 mg/kg; i.v. and p.o. once) shows good druggability and have a good effect in vivo after oral administration. |
| Target | HIV |
| XLogP3-AA | 3.5 |
